A Controlled Trial of Erenumab for Episodic Migraine
Top Cited Papers
- 30 November 2017
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 377 (22), 2123-2132
- https://doi.org/10.1056/nejmoa1705848
Abstract
We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene–related peptide receptor, for the prevention of episodic migraine.This publication has 27 references indexed in Scilit:
- A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache‐Related DisabilityHeadache: The Journal of Head and Face Pain, 2016
- Adherence to oral migraine-preventive medications among patients with chronic migraineCephalalgia, 2014
- The International Classification of Headache Disorders, 3rd edition (beta version)Cephalalgia, 2013
- MigraineCurrent Opinion in Neurology, 2013
- Chronic Migraine Prevalence, Disability, and Sociodemographic Factors: Results From the American Migraine Prevalence and Prevention StudyHeadache: The Journal of Head and Face Pain, 2012
- Current practice and future directions in the prevention and acute management of migraineThe Lancet Neurology, 2010
- Migraine prevalence, disease burden, and the need for preventive therapyNeurology, 2007
- Migraine — Current Understanding and TreatmentNew England Journal of Medicine, 2002
- The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and catsAnnals of Neurology, 1993
- Vasoactive peptide release in the extracerebral circulation of humans during migraine headacheAnnals of Neurology, 1990